^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

Excerpt:
Patients with BRAFV600-mutant glioma received vemurafenib 960 mg twice per day continuously...Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including malignant diffuse glioma (n = 11; six glioblastoma and five anaplastic astrocytoma),...Best response in patients with malignant diffuse glioma (n = 11) included one patient with PR, five with SD (two of whom had SD that lasted ≥ 6 months, thus meeting the definition for clinical benefit),...
DOI:
10.1200/JCO.2018.78.9990
Trial ID: